Table 3.
Competing risks regression analysis to test the association between cancer-specific mortality (CSM), after adjustment for other cause mortality (OCM), and type and number of high-risk criteria, in D’Amico high-risk prostate cancer (PCa) patients treated with external beam radiotherapy. Rates are stratified according to race-ethnicity.
| Competing-risks regression |
||||||||
|---|---|---|---|---|---|---|---|---|
| Caucasian |
African-American |
Hispanic-Latino |
Asian |
|||||
| HR (95% CI) | p-Value | HR (95% CI) | p-Value | HR (95% CI) | p-Value | HR (95% CI) | p-Value | |
| cT2c-3 | ref | ref | ref | ref | ||||
| PSA >20 | 1.10 (0.86–1.42) | 0.44 | 0.86 (0.54–1.38) | 0.54 | 0.52 (0.28–0.99) | 0.04 | 2.03 (0.64–6.48) | 0.23 |
| GGG 4–5 | 1.83 (1.52–2.2) | <0.001 | 1.55 (1.05–2.28) | 0.03 | 1.17 (0.73–1.88) | 0.51 | 2.59 (0.92–7.29) | 0.07 |
| PSA+cT | 2.47 (1.81–3.39) | <0.001 | 1.71 (0.93–3.17) | 0.09 | 0.66 (0.2–2.17) | 0.49 | 4.20 (0.94–18.64) | 0.06 |
| PSA+GGG | 3.66 (2.93–4.57) | <0.001 | 2.53 (1.61–3.96) | <0.001 | 1.67 (0.94–2.96) | 0.08 | 4.75 (1.58–14.26) | 0.01 |
| cT+GGG | 3.26 (2.64–4.02) | <0.001 | 3.33 (2.08–5.33) | <0.001 | 2.37 (1.32–4.26) | <0.001 | 3.4 (1.04–11.08) | 0.04 |
| cT+PSA+GGG | 4.99 (3.85–6.47) | <0.001 | 3.14 (1.78–5.52) | <0.001 | 3.03 (1.51–6.09) | <0.001 | 7.22 (2.04–25.51) | <0.001 |